Immutrin in £65 million Series A for ATTR amyloidosis drug

UK-based Immutrin, a biotech developing next generation antibody therapy to reverse amyloidosis, has successfully raised £65 million ($87 million) in a Series A financing.

The proceeds will fund Immutrin’s lead asset through clinical proof of concept in ATTR cardiomyopathy, a serious and often fatal form of amyloidosis, a group of rare, progressive diseases caused by misfolded proteins that aggregate into amyloid fibrils and accumulate in tissues and organs, leading to irreversible organ damage.